Ms Maureen B Riley, CRNA, BSN, MAE | |
10701 W Bell Rd, Sun City, AZ 85351-1074 | |
(602) 525-4977 | |
Not Available |
Full Name | Ms Maureen B Riley |
---|---|
Gender | Female |
Speciality | Nurse Anesthetist, Certified Registered |
Location | 10701 W Bell Rd, Sun City, Arizona |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1265527618 | NPI | - | NPPES |
132548 | Medicaid | AZ |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
367500000X | Nurse Anesthetist, Certified Registered | RN060004 (Arizona) | Primary |
Entity Name | Squaw Peak Anesthesia Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1548359128 PECOS PAC ID: 1153220728 Enrollment ID: O20040102000304 |
News Archive
Lightlake Therapeutics Inc., an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today that it intends to develop a treatment for premenstrual syndrome (PMS) overeating using its patented technology involving opioid antagonists.
Two experimental antiretroviral drugs, called TMC278 and elvitegravir, show promise in controlling the viral loads of HIV-positive people who have developed resistance to available drugs, researchers said Wednesday at the 14th Annual Conference on Retroviruses and Opportunistic Infections in Los Angeles, the Los Angeles Times reports.
Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common inherited kidney diseases. It's also one of the most common reasons that people require dialysis or transplantation...
Adaptimmune announced today that it has opened a Phase I/IIa, multiple-site, two-cohort, open-label clinical trial in ovarian cancer at Roswell Park Cancer Institute (RPCI) in Buffalo, N.Y., and City of Hope (COH) in Duarte, Calif.
› Verified 7 days ago
Entity Name | Gilbert Anesthesia Services Pllc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1265719579 PECOS PAC ID: 3375705999 Enrollment ID: O20120427000066 |
News Archive
Lightlake Therapeutics Inc., an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today that it intends to develop a treatment for premenstrual syndrome (PMS) overeating using its patented technology involving opioid antagonists.
Two experimental antiretroviral drugs, called TMC278 and elvitegravir, show promise in controlling the viral loads of HIV-positive people who have developed resistance to available drugs, researchers said Wednesday at the 14th Annual Conference on Retroviruses and Opportunistic Infections in Los Angeles, the Los Angeles Times reports.
Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common inherited kidney diseases. It's also one of the most common reasons that people require dialysis or transplantation...
Adaptimmune announced today that it has opened a Phase I/IIa, multiple-site, two-cohort, open-label clinical trial in ovarian cancer at Roswell Park Cancer Institute (RPCI) in Buffalo, N.Y., and City of Hope (COH) in Duarte, Calif.
› Verified 7 days ago
Entity Name | Az Care Anesthesia Plc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1043642796 PECOS PAC ID: 5799929907 Enrollment ID: O20130910000018 |
News Archive
Lightlake Therapeutics Inc., an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today that it intends to develop a treatment for premenstrual syndrome (PMS) overeating using its patented technology involving opioid antagonists.
Two experimental antiretroviral drugs, called TMC278 and elvitegravir, show promise in controlling the viral loads of HIV-positive people who have developed resistance to available drugs, researchers said Wednesday at the 14th Annual Conference on Retroviruses and Opportunistic Infections in Los Angeles, the Los Angeles Times reports.
Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common inherited kidney diseases. It's also one of the most common reasons that people require dialysis or transplantation...
Adaptimmune announced today that it has opened a Phase I/IIa, multiple-site, two-cohort, open-label clinical trial in ovarian cancer at Roswell Park Cancer Institute (RPCI) in Buffalo, N.Y., and City of Hope (COH) in Duarte, Calif.
› Verified 7 days ago
Entity Name | Atlantis Medical Group Az Pllc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1740610039 PECOS PAC ID: 7214168368 Enrollment ID: O20140402002039 |
News Archive
Lightlake Therapeutics Inc., an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today that it intends to develop a treatment for premenstrual syndrome (PMS) overeating using its patented technology involving opioid antagonists.
Two experimental antiretroviral drugs, called TMC278 and elvitegravir, show promise in controlling the viral loads of HIV-positive people who have developed resistance to available drugs, researchers said Wednesday at the 14th Annual Conference on Retroviruses and Opportunistic Infections in Los Angeles, the Los Angeles Times reports.
Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common inherited kidney diseases. It's also one of the most common reasons that people require dialysis or transplantation...
Adaptimmune announced today that it has opened a Phase I/IIa, multiple-site, two-cohort, open-label clinical trial in ovarian cancer at Roswell Park Cancer Institute (RPCI) in Buffalo, N.Y., and City of Hope (COH) in Duarte, Calif.
› Verified 7 days ago
Entity Name | Anesthesia Partners Of Arizona Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1619452901 PECOS PAC ID: 8628317179 Enrollment ID: O20190228001927 |
News Archive
Lightlake Therapeutics Inc., an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today that it intends to develop a treatment for premenstrual syndrome (PMS) overeating using its patented technology involving opioid antagonists.
Two experimental antiretroviral drugs, called TMC278 and elvitegravir, show promise in controlling the viral loads of HIV-positive people who have developed resistance to available drugs, researchers said Wednesday at the 14th Annual Conference on Retroviruses and Opportunistic Infections in Los Angeles, the Los Angeles Times reports.
Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common inherited kidney diseases. It's also one of the most common reasons that people require dialysis or transplantation...
Adaptimmune announced today that it has opened a Phase I/IIa, multiple-site, two-cohort, open-label clinical trial in ovarian cancer at Roswell Park Cancer Institute (RPCI) in Buffalo, N.Y., and City of Hope (COH) in Duarte, Calif.
› Verified 7 days ago
Mailing Address | Practice Location Address |
---|---|
Ms Maureen B Riley, CRNA, BSN, MAE Po Box 81024, Phoenix, AZ 85069-1024 Ph: (602) 525-4977 | Ms Maureen B Riley, CRNA, BSN, MAE 10701 W Bell Rd, Sun City, AZ 85351-1074 Ph: (602) 525-4977 |
News Archive
Lightlake Therapeutics Inc., an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today that it intends to develop a treatment for premenstrual syndrome (PMS) overeating using its patented technology involving opioid antagonists.
Two experimental antiretroviral drugs, called TMC278 and elvitegravir, show promise in controlling the viral loads of HIV-positive people who have developed resistance to available drugs, researchers said Wednesday at the 14th Annual Conference on Retroviruses and Opportunistic Infections in Los Angeles, the Los Angeles Times reports.
Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common inherited kidney diseases. It's also one of the most common reasons that people require dialysis or transplantation...
Adaptimmune announced today that it has opened a Phase I/IIa, multiple-site, two-cohort, open-label clinical trial in ovarian cancer at Roswell Park Cancer Institute (RPCI) in Buffalo, N.Y., and City of Hope (COH) in Duarte, Calif.
› Verified 7 days ago
Deanna Kay Villalino, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 10401 W Thunderbird Blvd, Sun City, AZ 85351 Phone: 623-832-4000 | |
Susan Marie Hawes, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 10401 W Thunderbird Blvd, Anesthesiology, Sun City, AZ 85351 Phone: 623-977-7211 Fax: 623-876-5697 | |
Susan Lassiter, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 10401 W Thunderbird Blvd, Sun City, AZ 85351 Phone: 623-977-7211 Fax: 623-876-5697 | |
Jay Rawlings, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 10401 W Thunderbird Blvd, Sun City, AZ 85351 Phone: 623-832-4000 | |
Mr. Gary Eddie Vesely, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 10541 W Thunderbird Blvd, Sun City, AZ 85351 Phone: 865-777-0909 Fax: 865-777-0910 | |
Ryker Sorenson, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 10401 W Thunderbird Blvd, Sun City, AZ 85351 Phone: 623-832-4000 |